Decapeptyl SR approved for use in early puberty

The GnRH analogue Decapeptyl SR (triptorelin) has been approved for the treatment of precocious puberty starting before eight years of age in girls, and before nine years of age in boys.

The recommended dose is one intramuscular injection of Decapeptyl SR 11.25 mg every three months. Treatment should be stopped around the physiological age of puberty; for girls, a bone maturation age of more than 12 years; for boys, a bone maturation age of 13 to 14 years.

Further information: Ipsen Ltd, 190 Bath Road, Slough, Berkshire SL1 3XE. Tel: (01753) 627777.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more